Frost & Sullivan Applauds Gamma Medica for Improving the Quality and Efficiency of Breast Cancer Diagnosis with its Unique LumaGEM MBI System
-- Gamma Medica meets the global demands of breast imaging by providing high sensitivity and specificity
MOUNTAIN VIEW, California, July 29, 2014 /PRNewswire/ -- Based on its recent analysis of the breast imaging systems market, Frost & Sullivan recognizes Gamma Medica with the 2014 Global Frost & Sullivan Award for Product Leadership. Gamma Medica's LumaGEM Molecular Breast Imaging (MBI) system provides breast images through the digital direct conversion of photons in gamma rays into electronic charges that form the image. It equips clinicians with MBI technology to detect tumors in women with dense breast tissue and plan treatment measures as early as possible.
Gamma Medica has demonstrated its dedication to improving the standard of care for breast cancer patients by offering the advanced cadmium zinc telluride (CZT) solid state detector technology in its LumaGEM MBI system.
"While other adjunct technologies such as ultrasound and magnetic resonance imaging are available, either their inability to locate microcalcifications or their low specificity can throw up inconclusive results," said Frost & Sullivan Research Analyst Raghuraman Madanagopal. "On the other hand, Gamma Medica's LumaGEM MBI system can efficiently locate lesions as small as 5 millimeters in size and help identify the tumor as benign or cancerous."
The LumaGEM MBI system has the highest negative predictive value (NPV) among adjunct technologies used for breast cancer diagnosis, making it one of the most reliable systems for this purpose. It also has a high intrinsic spatial resolution of 1.6 millimeters and provides high-quality images that enable clinicians to locate tumors, measure them, and understand their functional and metabolic activities.
While there are shortcomings with every adjunct technology that is used for breast cancer diagnosis, the LumaGEM MBI system, with a high sensitivity of 91 percent and a high specificity of 93 percent, offers customers unprecedented precision. The LumaGEM MBI system utilizes a dual-head technology that effectively locates cancers in cases that previously were either inconclusive or determined to be negative on mammography images.
As the imaging is done on the mediolateral oblique and the cranio-caudal planes, it is easily comparable to mammography images. The scanning procedure in the LumaGEM MBI system uses minimal compression and is performed with the subject in a seated position.
"The LumaGEM MBI system has a small-sized gamma camera that is located closer to the breasts," noted Raghuraman Madanagopal. "As a result, the amount of radiation required for obtaining images is less than one-third of the amount used in most breast-specific gamma imaging modalities. Frost & Sullivan research shows that this ability provides Gamma Medica a technological advantage over its competitors."
"Gamma Medica is committed to making MBI a more widely used tool in the battle against breast cancer," said Jim Calandra, president and chief executive officer of Gamma Medica. "We are pleased to have been recognized by Frost & Sullivan for our efforts and are excited to drive breast cancer diagnosis technology forward with highly advanced, patient-friendly and cost-effective tools."
Gamma Medica has made its products commercially available throughout the United States, as well as in certain parts of Europe, and hopes to expand to other regions of the world. By utilizing innovative technologies and effective growth strategies, Gamma Medica has ensured a superior competitive position for itself in the global breast imaging systems market.
Each year, Frost & Sullivan presents this award to the company that has demonstrated innovation in product features and functionality that provides enhanced quality and higher value to customers. The award recognizes the rapid acceptance such innovation finds in the marketplace.
Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.
About Gamma Medica
Gamma Medica, Inc. is dedicated to the development of advanced digital imaging technologies that address the growing importance of overcoming the critical shortcomings of mammography and other screening modalities in the early detection of breast cancer. The company designs, builds and services the LumaGEM® Digital MBI system, the first commercially available, FDA-cleared planar, dual head, fully solid-state digital imaging system utilizing cadmium zinc telluride (CZT) technology for molecular breast imaging. For more information, visit www.gammamedica.com.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
- The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
- The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Contact Us: Start the discussion
Subscribe: Newsletter on "the next big thing"
Register: Gain access to visionary innovation
Contact:
Mireya Espinoza
P: +1 210.247.3870
F: +1 210.348.1003
E: mireya.espinoza@frost.com
Sang Lee
VP of Sales and Marketing
P: +1.603.952.4441
E: media@gammamedica.com
Share this article